RegeniTherix™ Wound Theranostic System US patent granted
Neotherix is delighted to announce the grant of US patent 10,687,790 (“Sampling Device”) which covers the critical technology for the RegeniTherix™ device.
RegeniTherix is a theranostic system consisting of a bioresorbable electrospun polymer ‘scaffold’ to encourage growth of the patient’s own cells into the wound space to begin repair, and a thermo-switchable hydrogel to enable the collection and sampling of biomarkers produced by these reparative cells. RegeniTherix can be applied to a variety of chronic and non-healing wounds such as diabetic foot ulcers to monitor the physiological status of associated soft tissue and any underlying events or pathologies that may present a barrier to healing. The scaffold further functions to facilitate the healing of these tissues once such barriers have been identified and managed.
RegeniTherix received Bionow’s Project of the Year award in 2015 (Bionow). The granting of this patent is a major step towards the commercialisation of this innovative device.
We would like to thank Dr Peter Iddon and Dr Lorenzo Pio Serino for all their hard work and effort in developing RegeniTherix and Innovate UK and the National Institute for Health Research for funding.
We’re always happy to hear from potential investors and funding partners as well as researchers, universities and networks interested in our products and translational work.